Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

ALC vs IDXX vs HSIC vs HOLX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ALC
Alcon Inc.

Medical - Instruments & Supplies

HealthcareNYSE • CH
Market Cap$31.13B
5Y Perf.-1.5%
IDXX
IDEXX Laboratories, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$45.45B
5Y Perf.+81.3%
HSIC
Henry Schein, Inc.

Medical - Distribution

HealthcareNASDAQ • US
Market Cap$8.09B
5Y Perf.+16.6%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+42.6%

ALC vs IDXX vs HSIC vs HOLX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ALC logoALC
IDXX logoIDXX
HSIC logoHSIC
HOLX logoHOLX
IndustryMedical - Instruments & SuppliesMedical - Diagnostics & ResearchMedical - DistributionMedical - Instruments & Supplies
Market Cap$31.13B$45.45B$8.09B$16.97B
Revenue (TTM)$10.58B$4.45B$13.18B$4.13B
Net Income (TTM)$815M$1.10B$398M$544M
Gross Margin54.9%62.1%29.1%52.8%
Operating Margin12.3%31.6%5.8%17.5%
Forward P/E18.1x38.3x13.2x17.2x
Total Debt$5.25B$1.08B$3.69B$2.63B
Cash & Equiv.$1.53B$180M$156M$1.96B

ALC vs IDXX vs HSIC vs HOLXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ALC
IDXX
HSIC
HOLX
StockMay 20May 26Return
Alcon Inc. (ALC)10098.5-1.5%
IDEXX Laboratories,… (IDXX)100181.3+81.3%
Henry Schein, Inc. (HSIC)100116.6+16.6%
Hologic, Inc. (HOLX)100142.6+42.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: ALC vs IDXX vs HSIC vs HOLX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IDXX leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Hologic, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. ALC and HSIC also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ALC
Alcon Inc.
The Income Pick

ALC is the clearest fit if your priority is income & stability.

  • Dividend streak 5 yrs, beta 0.80, yield 0.5%
  • 0.5% yield; 5-year raise streak; the other 3 pay no meaningful dividend
Best for: income & stability
IDXX
IDEXX Laboratories, Inc.
The Growth Play

IDXX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 10.4%, EPS growth 22.6%, 3Y rev CAGR 8.5%
  • 5.6% 10Y total return vs HOLX's 124.3%
  • PEG 2.68 vs HSIC's 4.20
  • 10.4% revenue growth vs HOLX's 1.7%
Best for: growth exposure and long-term compounding
HSIC
Henry Schein, Inc.
The Value Play

HSIC is the clearest fit if your priority is value.

  • Lower P/E (13.2x vs 17.2x)
Best for: value
HOLX
Hologic, Inc.
The Defensive Pick

HOLX is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
  • Beta 0.41, current ratio 3.75x
  • Beta 0.41 vs IDXX's 1.35, lower leverage
  • +37.1% vs ALC's -32.6%
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthIDXX logoIDXX10.4% revenue growth vs HOLX's 1.7%
ValueHSIC logoHSICLower P/E (13.2x vs 17.2x)
Quality / MarginsIDXX logoIDXX24.6% margin vs HSIC's 3.0%
Stability / SafetyHOLX logoHOLXBeta 0.41 vs IDXX's 1.35, lower leverage
DividendsALC logoALC0.5% yield; 5-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)HOLX logoHOLX+37.1% vs ALC's -32.6%
Efficiency (ROA)IDXX logoIDXX32.6% ROA vs ALC's 2.6%, ROIC 42.5% vs 4.0%

ALC vs IDXX vs HSIC vs HOLX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ALCAlcon Inc.

Segment breakdown not available.

IDXXIDEXX Laboratories, Inc.
FY 2025
Product
59.0%$2.5B
Service
41.0%$1.8B
HSICHenry Schein, Inc.
FY 2018
Healthcare Distribution
96.1%$12.7B
Technology
3.9%$509M
HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M

ALC vs IDXX vs HSIC vs HOLX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIDXXLAGGINGHOLX

Income & Cash Flow (Last 12 Months)

IDXX leads this category, winning 5 of 6 comparable metrics.

HSIC is the larger business by revenue, generating $13.2B annually — 3.2x HOLX's $4.1B. IDXX is the more profitable business, keeping 24.6% of every revenue dollar as net income compared to HSIC's 3.0%. On growth, IDXX holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricALC logoALCAlcon Inc.IDXX logoIDXXIDEXX Laboratorie…HSIC logoHSICHenry Schein, Inc.HOLX logoHOLXHologic, Inc.
RevenueTrailing 12 months$10.6B$4.4B$13.2B$4.1B
EBITDAEarnings before interest/tax$2.2B$1.5B$1.1B$974M
Net IncomeAfter-tax profit$815M$1.1B$398M$544M
Free Cash FlowCash after capex$1.7B$845M$561M$1000M
Gross MarginGross profit ÷ Revenue+54.9%+62.1%+29.1%+52.8%
Operating MarginEBIT ÷ Revenue+12.3%+31.6%+5.8%+17.5%
Net MarginNet income ÷ Revenue+7.7%+24.6%+3.0%+13.2%
FCF MarginFCF ÷ Revenue+16.1%+19.0%+4.3%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year+7.3%+14.3%+7.7%+2.5%
EPS Growth (YoY)Latest quarter vs prior year-45.7%+16.6%+14.9%-9.2%
IDXX leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

HSIC leads this category, winning 5 of 7 comparable metrics.

At 21.6x trailing earnings, HSIC trades at a 51% valuation discount to IDXX's 43.7x P/E. Adjusting for growth (PEG ratio), IDXX offers better value at 3.06x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.

MetricALC logoALCAlcon Inc.IDXX logoIDXXIDEXX Laboratorie…HSIC logoHSICHenry Schein, Inc.HOLX logoHOLXHologic, Inc.
Market CapShares × price$31.1B$45.4B$8.1B$17.0B
Enterprise ValueMkt cap + debt − cash$34.9B$46.3B$11.6B$17.6B
Trailing P/EPrice ÷ TTM EPS32.26x43.75x21.56x30.53x
Forward P/EPrice ÷ next-FY EPS est.18.14x38.29x13.25x17.21x
PEG RatioP/E ÷ EPS growth rate3.06x6.84x
EV / EBITDAEnterprise value multiple13.66x31.60x10.87x17.39x
Price / SalesMarket cap ÷ Revenue2.99x10.56x0.61x4.14x
Price / BookPrice ÷ Book value/share1.44x28.75x1.79x3.43x
Price / FCFMarket cap ÷ FCF18.02x43.14x14.12x18.44x
HSIC leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

IDXX leads this category, winning 7 of 9 comparable metrics.

IDXX delivers a 70.9% return on equity — every $100 of shareholder capital generates $71 in annual profit, vs $4 for ALC. ALC carries lower financial leverage with a 0.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to HSIC's 0.77x. On the Piotroski fundamental quality scale (0–9), IDXX scores 7/9 vs HSIC's 4/9, reflecting strong financial health.

MetricALC logoALCAlcon Inc.IDXX logoIDXXIDEXX Laboratorie…HSIC logoHSICHenry Schein, Inc.HOLX logoHOLXHologic, Inc.
ROE (TTM)Return on equity+3.7%+70.9%+8.2%+11.0%
ROA (TTM)Return on assets+2.6%+32.6%+3.6%+6.1%
ROICReturn on invested capital+4.0%+42.5%+7.1%+9.4%
ROCEReturn on capital employed+4.8%+61.4%+9.8%+8.8%
Piotroski ScoreFundamental quality 0–96747
Debt / EquityFinancial leverage0.24x0.67x0.77x0.52x
Net DebtTotal debt minus cash$3.7B$897M$3.5B$667M
Cash & Equiv.Liquid assets$1.5B$180M$156M$2.0B
Total DebtShort + long-term debt$5.2B$1.1B$3.7B$2.6B
Interest CoverageEBIT ÷ Interest expense8.23x35.55x4.59x8.00x
IDXX leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — IDXX and HOLX each lead in 3 of 6 comparable metrics.

A $10,000 investment in HOLX five years ago would be worth $11,582 today (with dividends reinvested), compared to $8,746 for HSIC. Over the past 12 months, HOLX leads with a +37.1% total return vs ALC's -32.6%. The 3-year compound annual growth rate (CAGR) favors IDXX at 5.6% vs ALC's -4.5% — a key indicator of consistent wealth creation.

MetricALC logoALCAlcon Inc.IDXX logoIDXXIDEXX Laboratorie…HSIC logoHSICHenry Schein, Inc.HOLX logoHOLXHologic, Inc.
YTD ReturnYear-to-date-17.4%-14.6%-8.2%+1.9%
1-Year ReturnPast 12 months-32.6%+17.6%+5.9%+37.1%
3-Year ReturnCumulative with dividends-12.9%+17.9%-11.7%-8.5%
5-Year ReturnCumulative with dividends-6.7%+5.1%-12.5%+15.8%
10-Year ReturnCumulative with dividends+13.0%+556.2%+5.3%+124.3%
CAGR (3Y)Annualised 3-year return-4.5%+5.6%-4.0%-2.9%
Evenly matched — IDXX and HOLX each lead in 3 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than IDXX's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ALC's 65.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricALC logoALCAlcon Inc.IDXX logoIDXXIDEXX Laboratorie…HSIC logoHSICHenry Schein, Inc.HOLX logoHOLXHologic, Inc.
Beta (5Y)Sensitivity to S&P 5000.68x1.36x0.72x0.45x
52-Week HighHighest price in past year$97.14$769.98$89.29$76.04
52-Week LowLowest price in past year$63.84$471.74$61.95$52.81
% of 52W HighCurrent price vs 52-week peak+65.8%+74.3%+79.0%+100.0%
RSI (14)Momentum oscillator 0–10025.652.139.169.1
Avg Volume (50D)Average daily shares traded1.6M533K1.2M10.0M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

ALC leads this category, winning 1 of 1 comparable metric.

Analyst consensus: ALC as "Buy", IDXX as "Buy", HSIC as "Hold", HOLX as "Hold". Consensus price targets imply 35.5% upside for ALC (target: $87) vs 3.9% for HOLX (target: $79). ALC is the only dividend payer here at 0.52% yield — a key consideration for income-focused portfolios.

MetricALC logoALCAlcon Inc.IDXX logoIDXXIDEXX Laboratorie…HSIC logoHSICHenry Schein, Inc.HOLX logoHOLXHologic, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHoldHold
Price TargetConsensus 12-month target$86.52$747.50$85.43$79.00
# AnalystsCovering analysts26223242
Dividend YieldAnnual dividend ÷ price+0.5%
Dividend StreakConsecutive years of raises51
Dividend / ShareAnnual DPS$0.33
Buyback YieldShare repurchases ÷ mkt cap+2.3%+2.7%+10.5%+4.4%
ALC leads this category, winning 1 of 1 comparable metric.
Key Takeaway

IDXX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HSIC leads in 1 (Valuation Metrics). 1 tied.

Best OverallIDEXX Laboratories, Inc. (IDXX)Leads 2 of 6 categories
Loading custom metrics...

ALC vs IDXX vs HSIC vs HOLX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ALC or IDXX or HSIC or HOLX a better buy right now?

For growth investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Alcon Inc. (ALC) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ALC or IDXX or HSIC or HOLX?

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IDEXX Laboratories, Inc. wins at 2. 68x versus Henry Schein, Inc. 's 4. 20x.

03

Which is the better long-term investment — ALC or IDXX or HSIC or HOLX?

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -12. 5% for Henry Schein, Inc. (HSIC). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus HSIC's +5. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ALC or IDXX or HSIC or HOLX?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus IDEXX Laboratories, Inc. 's 1. 36β — meaning IDXX is approximately 201% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Alcon Inc. (ALC) carries a lower debt/equity ratio of 24% versus 77% for Henry Schein, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ALC or IDXX or HSIC or HOLX?

By revenue growth (latest reported year), IDEXX Laboratories, Inc.

(IDXX) is pulling ahead at 10. 4% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc. grew EPS 22. 6% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ALC or IDXX or HSIC or HOLX?

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus 3. 0% for Henry Schein, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 5. 7% for HSIC. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ALC or IDXX or HSIC or HOLX more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IDEXX Laboratories, Inc. (IDXX) is the more undervalued stock at a PEG of 2. 68x versus Henry Schein, Inc. 's 4. 20x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 2x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 25. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALC: 35. 5% to $86. 52.

08

Which pays a better dividend — ALC or IDXX or HSIC or HOLX?

In this comparison, ALC (0.

5% yield) pays a dividend. IDXX, HSIC, HOLX do not pay a meaningful dividend and should not be held primarily for income.

09

Is ALC or IDXX or HSIC or HOLX better for a retirement portfolio?

For long-horizon retirement investors, Alcon Inc.

(ALC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 68), 0. 5% yield). Both have compounded well over 10 years (ALC: +11. 4%, IDXX: +542. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ALC and IDXX and HSIC and HOLX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

ALC pays a dividend while IDXX, HSIC, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ALC

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

IDXX

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 14%
Run This Screen
Stocks Like

HSIC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 17%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ALC and IDXX and HSIC and HOLX on the metrics below

Revenue Growth>
%
(ALC: 7.3% · IDXX: 14.3%)
Net Margin>
%
(ALC: 7.7% · IDXX: 24.6%)
P/E Ratio<
x
(ALC: 32.3x · IDXX: 43.7x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.